{"id":47683,"date":"2022-08-25T23:02:15","date_gmt":"2022-08-25T21:02:15","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/quince-therapeutics-to-present-at-upcoming-scientific-meetings\/"},"modified":"2022-08-25T23:02:15","modified_gmt":"2022-08-25T21:02:15","slug":"quince-therapeutics-to-present-at-upcoming-scientific-meetings","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/quince-therapeutics-to-present-at-upcoming-scientific-meetings\/","title":{"rendered":"Quince Therapeutics to Present at Upcoming Scientific Meetings"},"content":{"rendered":"<div>\n<p>SOUTH SAN FRANCISCO, Calif.&#8211;(BUSINESS WIRE)&#8211;<a href=\"https:\/\/twitter.com\/search?q=%24QNCX&amp;src=ctag\" target=\"_blank\" rel=\"noopener\">$QNCX<\/a>&#8211;Quince Therapeutics, Inc. (Nasdaq: QNCX), a biopharmaceutical company advancing innovative precision therapeutics targeting debilitating and rare diseases, announced that the company will present at a number of scientific meetings taking place in September 2022, including the <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Foi2022.org%2F%23top&amp;esheet=52828734&amp;newsitemid=20220825005552&amp;lan=en-US&amp;anchor=14th+International+Conference+on+Osteogenesis+Imperfecta&amp;index=1&amp;md5=5a6c86c03d4a71ea1c19436b1e96ea9b\" rel=\"nofollow noopener\" shape=\"rect\">14<sup>th<\/sup> International Conference on Osteogenesis Imperfecta<\/a> (OI 2022), <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.asbmr.org%2Fannual-meeting&amp;esheet=52828734&amp;newsitemid=20220825005552&amp;lan=en-US&amp;anchor=The+American+Society+for+Bone+and+Mineral+Research+Annual+Meeting&amp;index=2&amp;md5=6cd266b22a090ecce2e7003300a4a920\" rel=\"nofollow noopener\" shape=\"rect\">The American Society for Bone and Mineral Research Annual Meeting<\/a> (ASBMR 2022), and the <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fmhsrs.health.mil%2FSitePages%2FHome.aspx&amp;esheet=52828734&amp;newsitemid=20220825005552&amp;lan=en-US&amp;anchor=Military+Health+System+Research+Symposium&amp;index=3&amp;md5=d5ef136392240ff30bb0a23ba2475b41\" rel=\"nofollow noopener\" shape=\"rect\">Military Health System Research Symposium<\/a> (MHSRS 2022). Meeting participation details are as follows:\n<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20220825005552\/en\/1528430\/5\/Quince_Therapeutics_Logo.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20220825005552\/en\/1528430\/21\/Quince_Therapeutics_Logo.jpg\"><\/a><\/p>\n<p>\n<b>OI 2022 \u2013 August 30 to September 2, 2022, in Sheffield, United Kingdom<\/b>\n<\/p>\n<p>\nAbstract Title: <i>Fracture-targeted Anabolics for Treatment of Osteogenesis Imperfecta Fractures<\/i>\n<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nPresenter: Karen Smith, M.D., Ph.D. \u2013 Chief Medical Officer, Quince Therapeutics\n<\/li>\n<li>\nAuthors: Stewart Low<sup>1<\/sup>, Jeffery Nielsen<sup>1<\/sup>, Xinlan Lu<sup>1<\/sup>, Arden Shen<sup>2<\/sup>, Mini Thomas<sup>1<\/sup>\n<\/li>\n<\/ul>\n<p>\n<b>ASBMR 2022 \u2013 September 9 to September 12, 2022, in Austin, Texas<\/b>\n<\/p>\n<p>\nAbstract Title: <i>Improved Spinal Fusion Through Targeted Delivery of Abaloparatide<\/i>\n<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nPresenter: Mini Thomas \u2013 Senior Scientist, Quince Therapeutics\n<\/li>\n<li>\nAuthors: Jeffery J. Nielsen<sup>1,2<\/sup>, Stewart A Low<sup> 1<\/sup>, Mini Thomas<sup>1<\/sup>,Christopher Chen<sup>1<\/sup>, Xinlan Li<sup>1<\/sup>, Ephraim Mbachu<sup>1<\/sup>, Lina Trigg<sup>2<\/sup>, Madeline Tremby<sup>2<\/sup>, Philip S. Low<sup>2<\/sup>\n<\/li>\n<\/ul>\n<p>\nAbstract Title: <i>: Evaluating the Efficacy of an Acidic Oligopeptide-radioisotope Chelator Conjugate to Target and Deliver Radioactive Agents to Bone Cancers<\/i>\n<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nPresenter: Da sol Jung \u2013 Graduate Student, Purdue University\n<\/li>\n<li>\nAuthors: Da sol Jung<sup>2<\/sup>, Philip S. Low<sup>2<\/sup>\n<\/li>\n<\/ul>\n<p>\n<b>MHSRS 2022 \u2013 September 12 to September 15, 2022, in Kissimmee, Florida<\/b>\n<\/p>\n<p>\nAbstract Title: <i>Engineered Bone Fracture Targeted Parathyroid Hormone Agonist as an Effective Pharmaceutical for Accelerated Bone Repair in Mouse and Canine Models<\/i>\n<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nPresenter: Mary Niedrauer \u2013 Scientist 2, Quince Therapeutics\n<\/li>\n<li>\nAuthors: Jeffery J. Nielsen<sup>1,2<\/sup>, Stewart A Low<sup> 1<\/sup>, Philip S. Low<sup>2<\/sup>\n<\/li>\n<\/ul>\n<p>\n<sup>1<\/sup>Quince Therapeutics, West Lafayette, IN <sup>2<\/sup>Purdue University, West Lafayette, IN\n<\/p>\n<p>\nQuince plans to post related presentations, posters, and abstracts to <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fquincetx.com%2Fscience%2F&amp;esheet=52828734&amp;newsitemid=20220825005552&amp;lan=en-US&amp;anchor=Science&amp;index=4&amp;md5=db08e22c56f58edd3a505132c6834fa7\" rel=\"nofollow noopener\" shape=\"rect\">Science<\/a> section of its <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fquincetx.com%2F&amp;esheet=52828734&amp;newsitemid=20220825005552&amp;lan=en-US&amp;anchor=corporate+website&amp;index=5&amp;md5=79f080583e015fcfb5318834a4193131\" rel=\"nofollow noopener\" shape=\"rect\">corporate website<\/a> in conjunction with its participation as these respective scientific meetings.\n<\/p>\n<p>\n<b>About Quince Therapeutics<\/b>\n<\/p>\n<p>\nQuince Therapeutics is focused on advancing innovative precision therapeutics targeting debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote more rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Quince\u2019s discovery pipeline is positioned for rapid expansion across multiple skeletal therapeutic indications to address underserved therapeutic areas with major, unmet medical needs, including osteogenesis imperfecta, fractures, spinal fusion, and other severe bone diseases. The company\u2019s lead compound NOV004 is an anabolic peptide engineered to precisely target and concentrate at the bone fracture site, which preclinical studies demonstrate result in rapid increases in bone density, strength, and healing directly at the site of bone fracture. NOV004 is expected to enter Phase 1 clinical studies in 2023 and advance to a lead indication in osteogenesis imperfecta. For more information, visit <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.quincetx.com&amp;esheet=52828734&amp;newsitemid=20220825005552&amp;lan=en-US&amp;anchor=www.quincetx.com&amp;index=6&amp;md5=d1a11616639fd60a27a44b875531d04e\" rel=\"nofollow noopener\" shape=\"rect\">www.quincetx.com<\/a> and follow Quince Therapeutics on LinkedIn and @Quince_Tx on Twitter.\n<\/p>\n<p>\n<b>Forward-looking Statements<\/b>\n<\/p>\n<p>\nStatements in this news release contain \u201cforward-looking statements\u201d that are subject to substantial risks and uncertainties. Forward-looking statements contained in this news release may be identified by the use of words such as \u201canticipate,\u201d \u201cexpect,\u201d \u201cwill,\u201d \u201ccan,\u201d \u201cmay,\u201d \u201cshould,\u201d \u201cestimate,\u201d \u201cproject,\u201d \u201cpotential,\u201d \u201cencouraged,\u201d \u201cpositioned,\u201d or other similar words. Examples of forward-looking statements include, among others, the clinical development and strategic development path for NOV004; the timing and success of the company\u2019s clinical trials and related data, including plans and the ability to initiate, conduct and\/or complete the Phase 1 clinical studies for NOV004; the potential therapeutic benefits, safety, and efficacy of the company\u2019s product candidate and discovery pipeline. Forward-looking statements are based on Quince Therapeutic\u2019s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict and could cause actual results to differ materially from what the company expects. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Factors that could cause actual results to differ include, but are not limited to, the risks and uncertainties described in the section titled \u201cRisk Factors\u201d in the company\u2019s Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on March 1, 2022, its Quarterly Report on Form 10-Q filed with the SEC on August 9, 2022, and other reports as filed with the SEC. Forward-looking statements contained in this news release are made as of this date, and Quince Therapeutics undertakes no duty to update such information except as required under applicable law.\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\nStacy Roughan<br \/>\n<br \/>Quince Therapeutics, Inc.<br \/>\n<br \/>Vice President, Corporate Communications &amp; Investor Relations<br \/>\n<br \/><a target=\"_blank\" href=\"&#109;&#x61;&#105;&#x6c;t&#x6f;:&#105;&#x72;&#64;&#x71;&#117;&#x69;n&#x63;e&#116;&#x78;&#46;&#x63;o&#x6d;\" rel=\"nofollow noopener\" shape=\"rect\">i&#114;&#x40;&#x71;u&#105;&#x6e;&#x63;e&#116;&#x78;&#x2e;c&#111;&#x6d;<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>SOUTH SAN FRANCISCO, Calif.&#8211;(BUSINESS WIRE)&#8211;$QNCX&#8211;Quince Therapeutics, Inc. (Nasdaq: QNCX), a biopharmaceutical company advancing innovative precision therapeutics targeting debilitating and rare diseases, announced that the company will present at a number of scientific meetings taking place in September 2022, including the 14th International Conference on Osteogenesis Imperfecta (OI 2022), The American Society for Bone and Mineral &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/quince-therapeutics-to-present-at-upcoming-scientific-meetings\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-47683","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Quince Therapeutics to Present at Upcoming Scientific Meetings - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/quince-therapeutics-to-present-at-upcoming-scientific-meetings\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Quince Therapeutics to Present at Upcoming Scientific Meetings - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"SOUTH SAN FRANCISCO, Calif.&#8211;(BUSINESS WIRE)&#8211;$QNCX&#8211;Quince Therapeutics, Inc. (Nasdaq: QNCX), a biopharmaceutical company advancing innovative precision therapeutics targeting debilitating and rare diseases, announced that the company will present at a number of scientific meetings taking place in September 2022, including the 14th International Conference on Osteogenesis Imperfecta (OI 2022), The American Society for Bone and Mineral ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/quince-therapeutics-to-present-at-upcoming-scientific-meetings\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-08-25T21:02:15+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220825005552\/en\/1528430\/21\/Quince_Therapeutics_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/quince-therapeutics-to-present-at-upcoming-scientific-meetings\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/quince-therapeutics-to-present-at-upcoming-scientific-meetings\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Quince Therapeutics to Present at Upcoming Scientific Meetings\",\"datePublished\":\"2022-08-25T21:02:15+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/quince-therapeutics-to-present-at-upcoming-scientific-meetings\\\/\"},\"wordCount\":734,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/quince-therapeutics-to-present-at-upcoming-scientific-meetings\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220825005552\\\/en\\\/1528430\\\/21\\\/Quince_Therapeutics_Logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/quince-therapeutics-to-present-at-upcoming-scientific-meetings\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/quince-therapeutics-to-present-at-upcoming-scientific-meetings\\\/\",\"name\":\"Quince Therapeutics to Present at Upcoming Scientific Meetings - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/quince-therapeutics-to-present-at-upcoming-scientific-meetings\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/quince-therapeutics-to-present-at-upcoming-scientific-meetings\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220825005552\\\/en\\\/1528430\\\/21\\\/Quince_Therapeutics_Logo.jpg\",\"datePublished\":\"2022-08-25T21:02:15+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/quince-therapeutics-to-present-at-upcoming-scientific-meetings\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/quince-therapeutics-to-present-at-upcoming-scientific-meetings\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/quince-therapeutics-to-present-at-upcoming-scientific-meetings\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220825005552\\\/en\\\/1528430\\\/21\\\/Quince_Therapeutics_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220825005552\\\/en\\\/1528430\\\/21\\\/Quince_Therapeutics_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/quince-therapeutics-to-present-at-upcoming-scientific-meetings\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Quince Therapeutics to Present at Upcoming Scientific Meetings\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Quince Therapeutics to Present at Upcoming Scientific Meetings - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/quince-therapeutics-to-present-at-upcoming-scientific-meetings\/","og_locale":"en_US","og_type":"article","og_title":"Quince Therapeutics to Present at Upcoming Scientific Meetings - Pharma Trend","og_description":"SOUTH SAN FRANCISCO, Calif.&#8211;(BUSINESS WIRE)&#8211;$QNCX&#8211;Quince Therapeutics, Inc. (Nasdaq: QNCX), a biopharmaceutical company advancing innovative precision therapeutics targeting debilitating and rare diseases, announced that the company will present at a number of scientific meetings taking place in September 2022, including the 14th International Conference on Osteogenesis Imperfecta (OI 2022), The American Society for Bone and Mineral ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/quince-therapeutics-to-present-at-upcoming-scientific-meetings\/","og_site_name":"Pharma Trend","article_published_time":"2022-08-25T21:02:15+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220825005552\/en\/1528430\/21\/Quince_Therapeutics_Logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/quince-therapeutics-to-present-at-upcoming-scientific-meetings\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/quince-therapeutics-to-present-at-upcoming-scientific-meetings\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Quince Therapeutics to Present at Upcoming Scientific Meetings","datePublished":"2022-08-25T21:02:15+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/quince-therapeutics-to-present-at-upcoming-scientific-meetings\/"},"wordCount":734,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/quince-therapeutics-to-present-at-upcoming-scientific-meetings\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220825005552\/en\/1528430\/21\/Quince_Therapeutics_Logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/quince-therapeutics-to-present-at-upcoming-scientific-meetings\/","url":"https:\/\/pharma-trend.com\/en\/quince-therapeutics-to-present-at-upcoming-scientific-meetings\/","name":"Quince Therapeutics to Present at Upcoming Scientific Meetings - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/quince-therapeutics-to-present-at-upcoming-scientific-meetings\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/quince-therapeutics-to-present-at-upcoming-scientific-meetings\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220825005552\/en\/1528430\/21\/Quince_Therapeutics_Logo.jpg","datePublished":"2022-08-25T21:02:15+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/quince-therapeutics-to-present-at-upcoming-scientific-meetings\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/quince-therapeutics-to-present-at-upcoming-scientific-meetings\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/quince-therapeutics-to-present-at-upcoming-scientific-meetings\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220825005552\/en\/1528430\/21\/Quince_Therapeutics_Logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220825005552\/en\/1528430\/21\/Quince_Therapeutics_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/quince-therapeutics-to-present-at-upcoming-scientific-meetings\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Quince Therapeutics to Present at Upcoming Scientific Meetings"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/47683","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=47683"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/47683\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=47683"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=47683"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=47683"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}